No evidence for core-binding factor CBFβ as a leukemia predisposing factor in chromosome 16q22-linked familial AML [7]

Leukemia

Volumn 18, Issue 4, 2004, Pages 881-

  Escher, R ^a   Hagos, F ^b   Michaud, J ^a   Sveen, L ^b   Horwitz, M ^c   Olopade, O I ^b   Scott, H S ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; CORE BINDING FACTOR BETA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SUSCEPTIBILITY; CHROMOSOME 16Q; CHROMOSOME TRANSLOCATION; FAMILIAL CANCER; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; GENETIC SUSCEPTIBILITY; HAPLOIDY; HEMATOPOIESIS; HETEROZYGOSITY; HETEROZYGOSITY LOSS; HUMAN; LETTER; LEUKEMOGENESIS; LINKAGE ANALYSIS; MUTATIONAL ANALYSIS; NORTHERN BLOTTING; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

EID: 4644267616     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403308     Document Type: Letter

References (8)

1. Horwitz M. The genetics of hematopoietic malignancy. In: King RA RJ, Motulsky AG (eds). The Genetic Basis of Common Disease. New York: Oxford University Press, 2002, pp 749-776.
2. Michaud J, Scott HS, Escher R. AML1 interconnected pathways of leukemogenesis. Cancer Invest 2003; 21: 105-136.
3. Crans HN, Sakamoto KM. Transcription factors and translocations in lymphoid and myeloid leukemia. Leukemia 2001; 15: 313-331.
4. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999; 23: 166-175.
5. Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood 2002; 99: 1364-1372.
6. Leroy H, Roumier C, Grardel-Duflos N, Macintyre E, Lepelley P, Fenaux P et al. Unlike AML1, CBFbeta gene is not deregulated by point mutations in acute myeloid leukemia and in myelodysplastic syndromes. Blood 2002; 99: 3848-3850.
7. Gao Q, Horwitz M, Roulston D, Hagos F, Zhao N, Freireich EJ et al. Susceptibility gene for familial acute myeloid leukemia associated with loss of 5q and/or 7q is not localized on the commonly deleted portion of 5q. Genes Chromosomes Cancer 2000; 28: 164-172.
8. Horwitz M, Benson KF, Li FQ, Wolff J, Leppert MF, Hobson L et al. Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2. Am J Hum Genet 1997; 61: 873-881.